Novo Nordisk’s bid to provide a once-weekly basal insulin product for people with diabetes, reducing the number of injections needed, has hit a major hurdle in the US. The FDA sent the Danish ...
The CEO of Novo Nordisk plans to blame drug middlemen for the high cost of popular diabetes and weight loss drugs Ozempic and Wegovy during a Senate hearing Wednesday ...
and is Novo Nordisk's third drug in the class after daily injectable Victoza (liraglutide) and weekly shot Ozempic, also based on semaglutide. The CHMP has issued a positive opinion for the drug ...
I’ll also detail where Novo Nordisk stands overall when it comes to the intense race for weight loss drug supremacy. Novo Shares Drop on Monlunabant Trial Results Novo shares fell 5% last Friday ...
It was a glaring omission given the fierce competition between Lilly and Novo, which has already resulted in lower drug prices. Prior to Tuesday’s hearing, I asked Barclays analyst Emily Field why ...